Ouro Medicines

Ouro Medicines is dedicated to developing immune reset therapeutics for people living with chronic immune-mediated diseases. Our approach is focused on leveraging T cell engagers in B cell mediated diseases to achieve immune resets that enable durable remissions without ongoing immunosuppression for patients. Based in San Francisco, Ouro was founded by Monograph Capital in partnership with GSK. We are also backed by leading investors TPG, NEA, Norwest and more.